

Book Reviews

Editorial Policy. Recently published books and journals (one copy) are invited by the Editorial Office for announcement and review in ANTICANCER RESEARCH (no fee). Each announcement should include the full title of the publication, authors or editors, the number of pages, price, year of publication, ISBN and publisher. Publishers will be notified upon receipt of books and tear sheets of reviews will be sent after publication. Books will be returned to the sender only if the announcement is rejected. Reviews will be objective and clear regarding the content, quality and usefulness of the publication.

Myeloma Therapy. Pursuing the Plasma Cell.

Edited by S. Lonial.

2008, pp. 663, US\$129.00, ISBN: 978-1-934115-82-4.
Humana Press, Totowa, NJ, USA.

Therapeutic options for patients with myeloma have radically changed over the past ten years. This volume provides updated various treatment options for patients with myeloma, with focus on the emerging and speculative aspects of myeloma therapy. Written by clearly acknowledged leaders in the field of myeloma therapy and research, *Myeloma Therapy: Pursuing the Plasma Cell* presents significant material on the biology and potential agents used to address specific signaling pathways, all of which are critical to myeloma biology and therapy. State of the art information from many of the leaders in the plasma cell disorders world includes disease pathogenesis and biology, chemotherapy based approaches, immune based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders. This book is a comprehensive collection and indispensable source in this time of rapid change in clinical and preclinical disease knowledge.

siRNA and miRNA Gene Silencing. From Bench to Bedside.

Edited by M. Sioud.

2009, pp. 472, US\$109.00, ISBN: 978-1-60327-546-0.
Humana Press, Totowa, NJ, USA.

RNA interference has become a key method in the suppression of gene expression and the development of therapeutic agents, yet there is still the problem of delivery, stability, and the danger of off-target effects such as the silencing of unwanted genes and activation of innate immunity. In this volume, expert researchers explore the most recent advances in siRNA design, expression, delivery, in vivo imaging, and methods to minimize siRNA's unwanted effects and promote successful use in patients. As part of the highly successful *Methods in Molecular Biology*TM series, the chapters focus on their respective subjects with easy-to-use, up-to-date information, including several step-by-step laboratory protocols on topics such as new delivery formulations and strategies with promising applications *in vitro* and *in vivo*, validated therapeutic target genes, and components of miRNA function, biogenesis, and interference with virus infection.

Comprehensive and cutting-edge, this book offers an excellent collection of chapters to aid all those with an interest in RNAi, gene regulation, and new therapies.

Handbook of Radiotherapy Physics. Theory and Practice.

Edited by P. Mayles, A. Nahum, J.-C. Rosenwald.

2007, pp. 1432, £150.00, ISBN: 0-7503-0860-5.
Taylor & Francis Group, Boca Raton, FL, USA.

From background physics and biological models to the latest imaging and treatment modalities, this volume covers all theoretical and practical aspects of radiotherapy physics. In this comprehensive reference, each part focuses on a major area of radiotherapy, beginning with an introduction by the editors and then subdividing into self-contained chapters. The first three parts present the fundamentals of the underlying physics, radiobiology, and technology involved. The ensuing sections discuss the support requirements of external beam radiotherapy, such as dose measurements, properties of clinical beams, patient dose computation, treatment planning, and quality assurance, followed by a part that explores exciting new advances that include developments in photon and particle therapy. Subsequent sections examine brachytherapy using sealed and unsealed sources and provide the framework of radiation protection. The final part contains handy tables of both physical constants and interaction coefficients.

With contributions from renowned specialists, this volume provides essential theoretical and practical knowledge to deliver safe and effective radiotherapy.

Nanotechnology for Cancer Therapy.

Edited by M.M. Amiji.

2007, pp. 817, £100.00, ISBN: 0-8493-7194-5.
CRC Press, Boca Raton, FL, USA.

While simultaneous breakthroughs occurring in molecular biology and nanoscience/technology will ultimately revolutionize all of medicine, it is with our efforts to prevent, diagnose, and treat cancer that many of the most dramatic advances will occur. In support of this potential, the U.S. National Cancer Institute (NCI) established the Alliance for Nanotechnology in Cancer in 2004 and pledged \$144.3 million in funding over the next five years.

Edited by one of the most dynamic pioneers in the field, *Nanotechnology for Cancer Therapy* focuses on those nanoscientific and nanotechnological strategies that are now evolving as the most effective and promising for the imaging and treatment of cancer. Among the various approaches considered, nanotechnology offers great possibilities for the targeted delivery of drugs and genes to tumor sites and the ultimate replacement of those chemotherapeutic agents so compromised by side effects.

Antiangiogenic Cancer Therapy.

Edited by D.W. Davis, R.S. Herbst, J.L. Abbruzzese.

2008, pp. 841, £109.00, ISBN: 0-8493-2799-7.
CRC Press, Boca Raton, FL, USA.

Given that solid tumors account for more than 85% of cancer mortality, and whereas tumor growth and metastasis are dependent on blood vessels, it makes sense that the targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, only the combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. To date, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors.

This volume promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis will lead to optimal therapeutic strategies. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject

Angiogenesis Protocols. 2nd Edition.

Edited by S. Martin, C. Murray.

2009, pp. 358, US\$99.50, ISBN: 978-1-58829-907-9.

Humana Press, Totowa, NJ, USA.

As experimentation and clinical trials with first generation anti-angiogenic agents have yielded results and our understanding of the biology and physiology of blood and lymphatic vessels has increased, a new angiogenesis volume swiftly became a necessity. *Angiogenesis Protocols, Second Edition* remains true to its original vision of providing a single source for angiogenesis researchers, irrespective of levels of resource and expertise, by collecting a range of methods for cell isolation and assessing angiogenesis in vivo or in vitro. This information, however, is expanded to include chapters on circulating endothelial progenitor cells, angiogenic signalling pathways, imaging of angiogenesis, and measurement of tissue blood flow. Written in the *Methods in Molecular Biology™* series format, the chapters provide step-by-step laboratory protocols, lists of necessary materials and reagents, and a Notes section, which details tips on troubleshooting and avoiding known pitfalls.

Extensive and cutting-edge, this volume is not only a practical handbook for key techniques, but also an informative and enjoyable read for all those interested, no matter how directly, in angiogenesis.

T Cell Protocols. 2nd Edition.

Edited by G. De Libero.

2009, pp. 165, Euro 71.64, ISBN: 978-1-58829-587-3.

Humana Press, Totowa, NJ, USA.

With a wide variety of investigative approaches, T cell immunology is a vital and open field of study. In *T Cell Protocols, Second Edition*, an international panel of experts contribute fully updated classic protocols as well as newly established novel techniques for the study of T lymphocyte biology.

Written in the highly successful *Methods in Molecular Biology™* series format, the chapters in this volume provide brief introductions to the topics, lists of the necessary materials and

reagents, step-by-step, readily reproducible laboratory protocols, and Notes sections which collect expert tips on troubleshooting and avoiding known pitfalls.

Up-to-date and easy to use, this volume is an ideal guide for young investigators new to the complex field of immunology as well as a valuable, concise resource for experienced scientists searching for clear, efficacious descriptions of novel methods.

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response.

Edited by F. Innocenti.

2008, pp. 377, US\$159.00, ISBN: 978-1-58829-646-7.

Humana Press, Totowa, NJ, USA.

As the traditional methods for selecting individualized drug therapies for patients proves increasingly less optimal, it becomes clear that new, molecular approaches to prescribing individual therapies are necessary in order to optimize benefits and minimize toxicities. In this book readers will find a series of articles that address the role of genomic information in cancer therapy and drug development. This volume is a unique resource, describing experimental approaches, statistical strategies, and clinical examples of the genomic applications in oncology. It represents the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

Contents: Part I: Genomic Experimental Approaches in Oncology. Toward the Realisation of the Promise of Microarrays in Oncology. Cell Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response. Proteomic Analysis in Cancer Patients. MicroRNAs and Discovery of New Targets. Pharmacogenomics of the National Cancer Institute's 60 Tumor Cell Panel. Use of Single Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbers. Part II: Pharmacogenomics of Toxicity and Response of Chemotherapy. Concordance Between Tumor and Germline DNA. Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. BCR-ABL Mutations and Imatinib Resistance in Chronic Myeloid Leukemia Patients. Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients. Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants in the Thiopurine S-Methyltransferase Gene. The Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies. DNA Repair and Mitotic Check Point Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer. Dihydropyrimidine Dehydrogenase (DPYD) Gene Polymorphism: Portrait of a Serial Killer. Impact of UDP-Glucuronosyltransferase 1A Haplotypes on Irinotecan Treatment. Microarray Profiling in Breast Cancer Patients. Role of the Folate Pathway and the Thymidylate Synthase Genes in Pediatric Acute Lymphoblastic Leukemia Treatment Response. Part III: Pharmacogenomics in Clinical Drug Development in Oncology. Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective. Identification of a Pharmacogenomic Biomarker Classifiers in Cancer Drug Development. Toxicogenomics Application to Oncology Drug Development. Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches. Index.

Epigenetics in Biology and Medicine.

Edited by M. Esteller.

2009, pp. 297, £79.00, ISBN: 978-0-8493-7289-6.

CRC Press, Boca Raton, FL, USA.

Anomalous epigenetic patterns touch many areas of study including biomedical, scientific, and industrial. With perspectives from international experts, this resource offers an all-inclusive overview of epigenetics, which bridge DNA information and function by regulating gene expression without modifying the DNA sequence itself.

In addition to covering histone modifications, and epigenomics, as well as dietary and environmental impacts on epigenetic changes, this book addresses these important questions:

- How promising are HDACi drugs as antitumor agents?
- Will restoring normal levels of miRNAs change the course of devastating diseases?
- Is it possible to alter epigenetic mechanisms once they are triggered?
- Is it possible to correct the abnormalities in methylation patterns that impact autoimmunities?

Cancer Epigenetics.

Edited by T. Tollefsbol.

2009, pp. 446, £79.00, ISBN: 978-1-4200-4579-6.

CRC Press, Boca Raton, FL, USA.

Elucidating the most recent advances in the genomic breakthrough of epigenetics, this cutting-edge work covers a wide array of aspects ranging from the role of epigenetics in the basic mechanisms of tumorigenesis, to the newest epigenetic drugs being developed and used for cancer therapy.

Cancer Epigenetics presents in-depth discussions of DNA methylation alterations, histone and RNA modifications, and nucleosome remodeling, which are all intimately involved in the formation of tumors. It also analyzes metabolic influences on cancer epigenetics and advances in epigenetic cancer gene therapy.

With stand-alone chapters authored by research pioneers in the field, this definitive resource:

- Discusses then recent advances in the role of epigenetics in tumor initiation, progression, and metastasis
- Describes the importance of dietary and environmental factors on cancer epigenetics
- Ranges from basic science to landmark discoveries in clinical practice
- Highlights diagnostic and prognostic aspects of epigenetics in cancer and advances in gene therapy
- Covers emerging aspects, such as RNA epigenetics, chromosomal position effects, and epigenomics, and the role of polycomb-group genes in cancer

This book is an indispensable reference for those with interests from the basic mechanisms of tumor biology to cancer therapy. Serving as a core textbook for advanced courses with a focus on genetic diseases, molecular biology, and/or cancer, this seminal work answers the call for a thorough and authoritative reference that covers the critical and contemporary aspects of this revolutionary field.

Bioinformatics in Cancer and Cancer Therapy.

Edited by G.J. Gordon.

2009, pp. 198, US\$149.00, ISBN: 978-1-58829-753-2.

Humana Press, Totowa, NJ, USA.

Bioinformatics can be loosely defined as the collection, classification, storage, and analysis of biochemical and biological information using computers and mathematical algorithms. Bioinformatics represents a marriage of biology, medicine, computer science, physics, and mathematics; fields of study that have historically existed as mutually exclusive disciplines. *Bioinformatics in Cancer and Cancer Therapy*, edited by Gavin Gordon, provides an historical and technical perspective on the analytical techniques, methodologies, and platforms used in bioinformatics experiments in order to show how a bioinformatics approach has been used to characterize various cancer-related processes, and to demonstrate how a bioinformatics approach is being used to bridge basic science and the clinical arena to positively impact patient care and management.

Cellular Respiration and Carcinogenesis.

Edited by S.P. Apte, R. Sarangarajan.

2009, pp. 195, US\$159.00, ISBN: 978-1-934115-07-7.

Humana Press, Totowa, NJ, USA.

This volume informs the reader about both basic and recent research in the field of cellular respiration and the effects of its dysfunction, alteration or attenuation on the development of cancer. This masterfully compiled text by leading experts in the field, offers the reader a fundamental understanding about how oxygen sensing and/or availability, programmed cell death, immune recognition and response and glucose metabolism are intimately linked with the two major mechanisms or pathways of cellular respiration; oxidative phosphorylation and glycolysis. The editors and contributing authors proficiently and unequivocally address the effects of dysfunction of the mitochondrial oxidative phosphorylation/glycolysis (cellular respiration) mechanisms and pathways on the development of cancer. While it remains true that there are no universal truths in cancer, *Cellular Respiration and Carcinogenesis* opens the dialogue that the etiology of cancer can usually be associated with and significantly attributed to the failure of one or multiple pathways of oxidative phosphorylation to normally burn fuel to generate energy, vis-à-vis the Warburg hypothesis. This book provides the first glimpse of cautionary evidence based counterbalance to the recent and rapidly proliferating notion that utilization of fuel primarily via glycolysis is a hallmark of cancer development.

Free Radicals Effect on Cytostatica, Vitamins, Hormones and Phytocompounds with Respect to Cancer.

By N. Getoff.

2008, pp. 132, £104.50, ISBN: 978-1-60456-291-0.

Nova Science Publishers, Inc., New York, NY, USA.

Free radicals generated in human organism, can also be produced by action of ionizing radiation in isolated aqueous systems. Hence, the knowledge of the fundamental radiation chemistry of

biological substances, combined with those of certain areas of biology, medicine and related domains, represent the frame of this young discipline. The molecular radiation biology has benefited very much from a number of experimental methods, which were successfully adopted from other disciplines. Its research area embraces a good deal of other medicine problems, particularly the combat of cancer in addition to the elucidation of biological reaction mechanisms induced by free radicals.

The book represents an attempt to demonstrate the advantage of new combined pathways of approach, showing particularly the importance of knowledge about the biological effect and consequences of free radicals action in organism.

Telomeres and Telomerase.

Edited by P. Slijepcevic.

2008, pp. 213, Euro 78.00, ISBN: 978-3-8055-9063-1.
S. Karger AG, Basel, Switzerland.

Telomeres are essential functional elements of eukaryotic chromosomes. Their fundamental biological role as protectors of chromosome stability was identified for the first time in the 1930s by Hermann Muller and Barbara McClintock based on pioneering cytological experiments. Modern molecular research carried out more recently revealed that telomeres and telomerase play important roles in processes such as carcinogenesis and cellular senescence.

This special issue presents the most recent developments in this highly active field of research. It is becoming increasingly clear that molecular pathways involved in regulation of telomere length and structure are functionally linked with pathways involved in DNA damage response, cellular stress response, chromatin organization and perhaps even pathways that regulate evolutionary chromosome rearrangements. The above functional link is explored by the leading experts in the field of telomere biology.

Cell biologists, molecular biologists, oncologists, gerontologists, and radiobiologists with an interest in the role of telomeres/telomerase will appreciate the up-to-date information in this publication.

FNA Cytology in the Diagnosis of Lymphoma.

By L. Skoog, E. Tani.

2009, pp. 77, Euro 94.50, ISBN: 978-3-8055-8626-9.
S. Karger AG, Basel, Switzerland.

Fine-needle aspiration (FNA) became important for the cytology of the enlarged lymph node in the 1950s and 1960s and was accepted in the diagnosis of various types of lymphadenitis and metastatic disease. The diagnosis of lymphoma by FNA cytology, however, remained controversial for many years, as FNA smears did not allow the evaluation of growth pattern. Only later with the introduction of immunocytochemistry on FNA material it became possible to conclusively diagnose the majority of lymphomas with an accuracy comparable to that of histopathology. Other ancillary techniques such as FISH and PCR can now also be applied successfully to FNA material. These facts together with the excellent clinical performance of FNA sampling should increase the spread of the technique.

This comprehensive manual presents the cytomorphologic and immunocytochemical characteristics of both non-Hodgkin and Hodgkin lymphomas. It discusses the technical, methodological aspects of lymphoma diagnosis and describes the cytologic features of reactive lymphoid lesions and the major types of neoplastic lymphoid lesions, based on the most recent (2001) WHO lymphoma classification. Key cytologic and immunologic features are listed to facilitate a conclusive diagnosis of the different lesions.

This publication will be of interest to clinicians such as cytopathologists, pathologists, oncologists, and hematologists involved in the clinical work-up and management of patients with lymph node lesions.

Cancer Epidemiology. Volume 1, Host Susceptibility Factors.

Volume 2, Modifiable Factors.

Edited by M. Verma.

2009, pp. 507 + 484, US\$99.50 each, ISBN: 978-1-58829-987-1 (Vol.1); 978-1-60327-491-3 (Vol. 2).
Humana Press, Totowa, NJ, USA.

Population studies and epidemiology facilitate the discovery of genetic and environmental determinants of cancer and the development of new approaches to cancer control and prevention, therefore they play a central role in the creation of health policies. *Cancer Epidemiology* compiles areas of research which cover etiological factors or determinants that contribute to the development of cancer and describe the the latest technologies in cancer epidemiology. In Volume 1, Host Susceptibility Factors, leading experts provide 25 chapters on cancer incidence, prevalence, mortality and surveillance, methods, technologies and study design in cancer epidemiology as well as host susceptibility factors in cancer epidemiology.

In *Volume 2, Modifiable Factors*, 23 comprehensive chapters cover the various topics on modifiable factors in cancer epidemiology, epidemiology of organ specific cancer, and environmental and life style factors. Although a non-standard volume of the highly successful *Methods in Molecular Biology*TM series, this comprehensive text retains the commitment of the series to collecting the kind of detailed, up-to-date information and implementation advice that is crucial for getting optimal results.

Chemistry and Pharmacology of Anticancer Drugs.

By D.E. Thurston.

2007, pp. 290, £79.00, ISBN: 0-8493-9219-5.
CRC Press, Boca Raton, FL, USA.

While drug therapies developed in the last 50 years have markedly improved the management of some types of cancers, treatment outcomes, and drug side-effects for the most common types remain unacceptable. However, recent technological advances are leading to improved therapies based on targeting distinct biological pathways in cancer cells. *Chemistry and Pharmacology of Anticancer Drugs* is a comprehensive survey of all families of anticancer agents currently in use or in advanced stages of clinical trials, including biologicals.

The book is unique in providing molecular structures for all anticancer drugs, discussing them in terms of history, chemistry, mechanism of action, structure-function relationships, and pharmacology. It also provides some relevant information on side effects, dosing, and formulation. The author, a renowned scientist in cancer research and drug development, also provides up-to-date information on the drug discovery process, including new research tools, tumor-targeting strategies, and fundamental concepts in the emerging areas of personalized medicine (e.g., oncogenomics) and chemoprevention.

Features: Summarizes the fundamental causes of cancer, modes of treatment, and the philosophy of cancer drug discovery; Brings together a broad spectrum of information relating to the chemistry and pharmacology of anticancer drugs and therapies; Covers all types of anticancer drugs including biological agents and many in the research, development, and clinical evaluation stages; Provides molecular structures and generic/trade names for each agent, along with information on chemistry, mechanism of action, and side effects/dose scheduling where appropriate; Introduces cutting-edge research methodologies and tools being used to discover and develop new anticancer drugs and therapies; Describes the new areas of oncogenomics and chemoprevention.

This volume is an indispensable resource for cancer researchers, medicinal chemists, and other biomedical scientists involved in the development of new anticancer treatments. Its breadth of coverage also makes it suitable for undergraduate and postgraduate courses in medicine, pharmacy, nursing, and related disciplines.

Cancer and the Search for Selective Biochemical Inhibitors. Second Edition.

By E.J. Hoffman.

2007, pp. 461, £82.00, ISBN: 1-4200-4593-8.

CRC Press, Boca Raton, FL, USA.

This book delineates the underlying biochemical principles for alternative cancer therapies. Completely revised and updated, this edition includes coverage of the link between concepts and practices of alternative and conventional medicine. The author examines anticancer plant substances and other alternatives such as Vitamin C, essiac tea, shark cartilage, and cat's claw. The text also addresses the problem of determining selective and non-toxic enzyme inhibitors for cancer cell metabolic pathways.

While an increased number of allopathic professionals are in tune with alternative therapies, the integration of the two factions is far from the norm. This book delineates complementary, alternative, and integrative treatments with chemotherapy and other more traditional treatments.

Supportive Care in Cancer Therapy.

Edited by D.S. Ettinger.

2009, pp. 294, Euro 123.00, ISBN: 978-1-58829-941-3.

Humana Press, Totowa, NJ, USA.

Supportive care of the cancer patient begins with the diagnosis of cancer and terminates with the end of life. Supportive care is for

symptoms related to the cancer and its treatment, including all of the physical, psychosocial and emotional issues associated with the cancer. In general, patients with cancer are living longer today: Even those with advanced, metastatic disease have an increase in the length of their survival. This is, in part, due to better therapies, novel treatments and the multimodality approaches used in treating many cancers. The contributors of this volume provide an up-to-date, concise review of specific consequences of cancer and its treatment. The chapters will allow the reader to better understand the sequelae associated with all aspects of cancer and how to treat them in order to achieve control of symptoms and provide psychosocial care to improve the quality of life of the cancer patient. In addition, the reader will gain information on the care of the older patient as well as the dying patient.

Contents: Management of Dyspnea. Skeletal Metastases: Optimal Management Today. Cancer Pain. Anorexia and Cachexia. Fatigue. Pathogenesis and Management of Venous Thromboembolism in Cancer. Depression in Cancer Patients. Anemia. Neutropenia. Nausea and Vomiting. Oral Mucositis. Diarrhea and Constipation: Supportive Oncology Management. Menopausal Symptoms. Supportive Care of the Older Cancer Patient. Integrative Oncology: Complementary Therapies in Cancer Care. End of Life Decisions. Index

CRC Handbook of Chemistry and Physics on CD-Rom. Version 2009.

Editor-in-Chief: D.R. Lide.

2009, £90.00, ISSN: 1098-4178.

CRC Press, Boca Raton, FL, USA.

Augmented by a series of practical utilities, the *CRC Handbook of Chemistry and Physics on CD-Rom, Version 2009* contains all of the information found in the most recent print edition - in a conveniently searchable electronic format. A mainstay for scientists around the world for more than 90 years, the Handbook continues to evolve with major updates, expansions, new tables, and updated references.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.

Edited by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe,

S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman.

2008, pp. 439, ISBN: 978-92-832-2431-0.

IARC, Lyon, France.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is the second volume of the 4th Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome.

Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, incidence, age and sex distribution, location, clinical signs and symptoms, pathology, genetics and predictive factors.

The book, prepared by more than 130 authors from 24 countries, contains about 1000 colour photographs, numerous charts and more than 2,500 references.

IARC Monograph on the Evaluation of Carcinogenic Risks to Humans.

Volume 97: 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide).

2008, pp. 510, ISBN: 978 92 832 1297 3.

IARC, Lyon, France.

This volume represents the views and expert opinions of an IARC working group on the evaluation of carcinogenic risks and hazards to humans, who met in Lyon, 5-12 June, 2007. The book includes authoritative description of the data on the carcinogenic effects of 1,3-butadiene, ethylene oxide and vinylhalides in studies in experimental animals, in cell cultures as well as in humans.

Breast Cancer Sourcebook. Third Edition.

Edited by K. Bellemir.

2009, pp. 606, ISBN: 978-0-7808-1030-3

Omingraphics, Detroit, MI, USA.

Breast Cancer Sourcebook, Third Edition, provides updated information about breast health and breast cancer risk factors. It explains the different types of breast cancer, including breast cancer associated with different genes, inflammatory breast cancer, Paget disease of the nipple, and breast cancer in men. It discusses how screening for breast cancer with mammography, clinical breast exams, and self-exams may help doctors find and treat cancer early when treatments are more likely to be effective. Cancer treatment options, including surgery, radiation therapy, chemotherapy, and biological therapy are described, and the emotional concerns of women in and after treatment are addressed. A section on research advances offers information from recent clinical trials, and the book concludes with a glossary and directories of resources for additional help and support.

Announcements

3rd International Congress of Molecular Medicine.

5-8 May 2009, Istanbul, Turkey.

Information: Prof. T. Isbir, e-mail: molekuler2009@molekuler2009.org; www.molekulertip.org

First International Symposium on Proton Transport and its Inhibition (ITP) in the Etiopathogenesis, Diagnosis and Treatment of Cancer.

28-29 April 2009, Madrid, Spain.

Information: www.fundacionareces.es

12th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Symposium.

3-6 June 2009, Toronto, Canada.

Information: www.cspscanada.org

23rd International Congress on Computer Assisted Radiation and Surgery (CARS 2009).

23-27 June 2009, Berlin, Germany.

Information: www.cars-int.org

5th International Conference on Tumor Microenvironment.

20-24 October, 2009, Versailles, France.

Information: www.cancermicroenvironment.tau.ac.il

World Conference on Regenerative Medicine.

29-31 October 2009, Leipzig, Germany.

Information: www.wcrm-leipzig.com

online from January 2009



in vivo

International Journal of Experimental and Clinical
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN: 0258-851X

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iia-anticancer.org

For more information about IN VIVO, IAR and the conferences please visit the IAR website: www.iia-anticancer.org

Selection of Recent Articles

Investigation of the Effects of Aging on Homologous Recombination in Long Term Bone Marrow Cultures. M.W. EPPERLY, R. RUGO, S. CAO, H. WONG, D. FRANICOLA, J.P. GOFF, H. SHEN, X. ZHANG, D. WIKTOR-BROWN, B.P. ENGELWARD, J.S. GREENBERGER (*Pittsburgh, PA; Cambridge, MA, USA*)

Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RADY, J. HULSTAERT, K. DE MEIRLEIR (*Zellik; Brussels; Vilvoorde, Belgium*)

Failure of α -Galactosylceramide to Prevent Diabetes in Virus-Inducible Models of Type 1 Diabetes in the Rat. P. CHOPRA, P. DI IORIO, S.C. PINO, S.B. WILSON, N.E. PHILLIPS, J.P. MORDES, A.A. ROSSINI, D.L. GREINER, L.D. SHULTZ, R. BORTELL (*Worcester; Cambridge, MA; Bar Harbor, ME, USA*)

Drug Resistance of Human Immunodeficiency Virus and its Overcoming by Natural Products, A Review. J. HUPFELD, T. EFFERTH (*Heidelberg, Germany*)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increases Adenoma and flat ACF Number in the Intestine of *Min/+* mice. C. RÖNNINGBORG, T. HUSØY, H. GLATT, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway; Nuthetal, Germany*)

Distribution of [3 H]corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats after Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, J. NYMAN, R. GOLDKUHL, J. HAU (*Uppsala, Sweden; Copenhagen, Denmark*)

Dietary Calcium Source Influences Body Composition, Glucose Metabolism, and Hormone Levels in a Mouse Model of Postmenopausal Obesity. R.E. DE ANGEL, D. BERRIGAN, N.P. NÚÑEZ, S.D. HURSTING, S.N. PERKINS (*Austin; Smithville, TX; Bethesda, MD, USA*)

In Vivo Studies on the Availability and Toxicity of Antisense-oligonucleotides in Bladder Cancer. C.E. BLIETZ, B. THODE, M. HAUSES, R. PRIES, A.J. MEYER, C. DOEHN, D. JOCHAM, I. KAUSCH (*Lübeck; Leipzig, Germany*)

Auricular Chondrocytes – From Benchwork to Clinical Applications. C. NABZDYK, J. MOLINA, E. PERIN, D. PANIAGUA, D. ROSENSTRAUCH (*Berlin, Germany; Houston, TX, USA*)

Effects of Neonatal Administration of Diethylstilbestrol on Aberrant Crypt Foci Induced by 7,12-Dimethylbenz[a]anthracene in Rats. H. KAWASHIMA, H. KAWAGUCHI, Y. UMEKITA, M. SOUDA, K. GEJIMA, T. KOMOKATA, R. SAKATA, H. YOSHIDA (*Kagoshima, Japan*)

MnSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status. T. IGUCHI, S. SUGITA, C.Y. WANG, N.B. NEWMAN, T. NAKATANI, G.P. HAAS (*Syracuse, NY, USA; Osaka, Japan*)


Selective Anti-bacterial and Apoptosis-modulating Activities of Mastic. H. SAKAGAMI, K. KISHINO, M. KOBAYASHI, K. HASHIMOTO, A. SHIMETANI, Y. NAKAMURA, K. TAKAHASHI, T. IKARASHI, H. FUKAMACHI, K. SATOH, H. NAKASHIMA, T. SHIMIZU, K. TAKEDA, S. WATANABE, W. NAKAMURA (*Saitama; Fukushima; Tokyo; Kanagawa; Chiba, Japan*)

Immunohistochemical Staining of Mucin 1 in Prostate Tissues. N. RABIAU, P. DÉCHELOTTE, L. GUY, S. SATHI, R. BOSVIEL, L. FONTANA, J.-L. KEMENY, J.-P. BOITEUX, Y.-J. BIGNON, D. BERNARD-GALLON (*Clermont-Ferrand, France*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, *^oDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (*Duarte, CA, USA*)

Molecular Mechanisms of Action of Imatinib Mesylate in Human Ovarian Cancer: A Proteomic Analysis. B.B. PATEL, Y.A. HE, X.-M. LI, A. FROLOV, L. VANDERVEER, C. SLATER, R.J. SCHILDER, M. VON MEHREN, A.K. GODWIN, A.T. YEUNG (*Philadelphia, PA; Birmingham, AL, USA*)

Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (*Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA*)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (*Kiel; Tuebingen, Germany*)

Immune Response Signatures of Benzo(α)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (*Morgantown, WV, USA*)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (*Uppsala; Stockholm, Sweden*)

Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis. I.L. BOTCHKINA, R.A. ROWEHL, D.E. RIVADENEIRA, M.S. KARPEH Jr., HOWARD CRAWFORD, A. DUFOUR, J. JU, Y. WANG, Y. LEYFMAN, G.I. BOTCHKINA (*San Francisco, CA; Stony Brook, New York, NY, USA*)

Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (*Giessen, Germany*)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (*Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA*)

A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Poststate Cancer. P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, H.M. COLEY (*Surrey, UK*)

Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (*Cardiff, UK*)

Down-regulation of Microfilament Network-Associated Proteins in Leukocytes of Breast Cancer Patients: Potential Application to Predictive Diagnostics. M. BRAUN, M. FOUNTOULAKIS, A. PAPAPOPOULOU, K. VOUGAS, I. SEIDEL, T. HÖLLER, K. YEGHIAZARYAN, H.H. SCHILD, W. KUHN, O. GOLUBNITSCHAJA (*Bonn, Germany; Athens, Greece*)

Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (*Stony Brook, NY, USA*)

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept high quality original works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy advises that priority should be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a) abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) announcements of meetings related to cancer research; (c) short reviews (of approximately 1,200 words) and announcements of newly published books and journals related to cancer; and (d) announcements of awards and prizes.

The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in AR, for public archiving in PubMed Central.

A main aim of AR is to ensure the prompt publication of high quality original works, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on cancer that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts in terms of grammar and style.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all the essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced page), including abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, indication of the study type "clinical", "epidemiological", or "experimental", and date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

References. Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones.* O' Malley BW and Chamnes GC (eds.). New York, Plenum Publ Corp, pp. 113-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

Submission of Manuscripts. You can send your article via e-mail to journals@iiar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. **OR** You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS. 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014, Kapandriti, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each published article will be provided free-of-charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Multicenter Phase II Trial of First-line Docetaxel/Gemcitabine in Advanced Breast Cancer Pretreated with Adjuvant Anthracyclines. P. VICI, F. GIOTTA, L. DI LAURO, M. BRANDI, V. GEBBIA, P. FOGGI, V. LORUSSO, C. VITUCCI, D. SERGI, S.I. FATTORUSO, D. GIANNARELLI, G. VIOLA, S. CORSETTI, G. COLUCCI, M. LOPEZ (<i>Rome; Bari; Palermo; Lecce, Italy</i>)	1841
Effects of the Conventional Antitumor Therapies Surgery, Chemotherapy, Radiotherapy and Immunotherapy on Regulatory T Lymphocytes in Cancer Patients. P. LISSONI, F. BRIVIO, L. FUMAGALLI, G. MESSINA, S. MEREGALLI, G. PORRO, F. ROVELLI, L. VIGORÈ, E. TISI, G. D'AMICO (<i>Monza, Milan, Italy</i>)	1847
Local Recurrence following Adjuvant Chemotherapy without Radiotherapy in Completely Resected Stomach and Gastroesophageal Junction Adenocarcinoma. G. BAR-SELA, M. TSALIC, M. STEINER, M. WOLLNER, N. HAIM (<i>Haifa, Israel</i>)	1853
Erratum	1857
* Review (pages 1551, 1823)	

Topotecan-induced Long-term Remission of an Advanced Endometrial Cancer After Treatment with Cisplatinum, an Anthracycline and Paclitaxel. T. IDRIS, R. WINTER, U. LANG, E. PETRU (<i>Graz, Austria</i>)	1761
Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation for 30 Adults with Hematological Malignancies. K. KOBAYASHI, Y. MAEDA, Y. HARA, M. NISHIE-KATAOKA, H. NISHIMORI, H. SUGIYAMA, N. NAMBA, S. KUBONISHI, M. NIIYA, K. SHINAGAWA, K. IKEDA, M. TANIMOTO (<i>Okayama, Japan</i>)	1763
Correlation of Nuclear Morphometry of Breast Cancer in Histological Sections with Clinicopathological Features and Prognosis. F. ABDALLA, J. BODER, R. MARKUS, H. HASHMI, A. BUHMEIDA, Y. COLLAN (<i>Turku, Finland; Tripoli; Sabratha, Libya</i>)	1771
Significant Association of an XRCC4 Single Nucleotide Polymorphism with Bladder Cancer Susceptibility in Taiwan. C.-H. CHANG, C.-L. CHANG, C.-W. TSAI, H.-C. WU, C.-F. CHIU, R.-F. WANG, C.-S. LIU, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	1777
Treatment of Patients with Unresectable Advanced Carcinoma of Biliary Tract – Chemotherapy and Surgical Resection. Z. MORISE, A. SUGIOKA, Y. TANAHASHI, Y. OKABE, M. IKEDA, T. KAGAWA, C. TAKEURA (<i>Aichi, Japan</i>)	1783
Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer. P. WIMBERGER, M. HEUBNER, H. LINDHOFER, M. JÄGER, R. KIMMIG, S. KASIMIR-BAUER (<i>Essen; Munich; Martinsried, Germany</i>)	1787
Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign). J. MASHIAH, S. BRENNER, Y. PESSACH, V. BARAK, J. SCHACHTER (<i>Tel Aviv; Jerusalem, Israel</i>)	1793
Continuous Finasteride Therapy for Benign Prostate Hypertrophy Upgrades Both Neuroendocrine Differentiation and Aggressive Prostate Cancer. M. TARLE, B. SPAJIC, I. KRALJIC, Z. KUSIC (<i>Zagreb, Croatia</i>)	1797
Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer. C. SALEK, P. MINARIKOVA, L. BENESOVA, V. NOSEK, R. STRNAD, M. ZAVORAL, M. MINARIK (<i>Prague, Czech Republic</i>)	1803
Mutation Analysis of IgVH Genes in Splenic Marginal Zone Lymphomas: Correlation with Clinical Characteristics and Outcome. C. KALPADAKIS, G.A. PANGALIS, E. DIMITRIADOU, M.K. ANGELOPOULOU, M.P. SIAKANTARIS, M.-C. KYRTSONIS, M. XIMERIS, T. TZENOU, S. SAHANAS, X. YIAKOUMIS, E.A. PAPADAKI, P. PANAYIOTIDIS, T. VASSILAKOPOULOS (<i>Athens; Heraklion, Greece</i>)	1811
Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung. Y. KIM, H.S. KIM, Z.Y. CUI, H.-S. LEE, J.S. AHN, C.K. PARK, K. PARK, M.-J. AHN (<i>Seoul, South Korea</i>)	1817
* Review: Molecular Imaging of Tumor Blood Vessels in Prostate Cancer. D. TILKI, M. SEITZ, B.B. SINGER, S. IRMAK, C.G. STIEF, O. REICH, S. ERGÜN (<i>Munich; Essen, Germany; New York, NY, USA</i>)	1823
Clinical Correlations between Treatment with Anticoagulants/Antiaggregants and Late Rectal Toxicity after Radiotherapy for Prostate Cancer. K. TAKEDA, Y. OGAWA, H. ARIGA, M. KOTO, T. SAKAYAUCHI, K. FUJIMOTO, K. NARAZAKI, M. MITSUYA, Y. TAKAI, S. YAMADA (<i>Sendai, Japan</i>)	1831
Single Nucleotide Polymorphisms and Clinical Outcome in Patients with Biliary Tract Carcinoma Treated with Epirubicin, Cisplatin and Capecitabine. P. PACETTI, E. GIOVANNETTI, A. MAMBRINI, S. NANNIZZI, M. ORLANDI, R. TARTARINI, A. DEL FREO, M. DEL TACCA, R. DANESI, M. CANTORE (<i>Carrara; Pisa, Italy</i>)	1835

Lymphatic Vessel Density in Correlation to Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. S. FRECH, K. HÖRMANN, F. RIEDEL, K. GÖTTE (<i>Mannheim, Germany</i>)	1675
Clinicopathological Features of Perforated Colorectal Cancer. M. OGAWA, M. WATANABE, K. ETO, T. OMACHI, M. KOSUGE, K. HANYU, L. NOAKI, T. FUJITA, K. YANAGA (<i>Tokyo, Japan</i>)	1681
Expression of Matriptase and Clinical Outcome of Human Endometrial Cancer. K. NAKAMURA, A. HONGO, J. KODAMA, F. ABARZUA, Y. NASU, H. KUMON, Y. HIRAMATSU (<i>Okayama, Japan</i>)	1685
Immunohistochemical Detection of WT1 Protein in Endometrial Cancer. S. OHNO, S. DOHI, Y. OHNO, S. KYO, H. SUGIYAMA, N. SUZUKI, M. INOUE (<i>Ishikawa; Tokyo; Osaka, Japan</i>)	1691
Prognosis for Isolated Skin Recurrence after Breast Cancer Treated by Mastectomy. F. JAFFRE, V. LAVOUE, H. MESBAH, S. ROUQUETTE, O. AUDRAIN, J.F. LAURENT, J. LEVEQUE (<i>Rennes, France</i>)	1697
Kinetics of HER2/neu ECD in 45 Patients Treated with Trastuzumab (Herceptin®) between January 2001 and June 2005 at the Grenoble University Hospital. A.-S. GAUCHEZ, M. COLONNA, F.-X. BRAND, N. RAVANEL, D. PASQUIER, R. PAYAN, M. MOUSSEAU (<i>Meylan; Saint Martin d'Hères; Grenoble, France</i>)	1703
GSTM1 and NAT2 Polymorphisms and Colon, Lung and Bladder Cancer Risk: A Case-control Study. A. ZUPA, A. SGAMBATO, G. BIANCHINO, G. IMPROTA, V. GRIECO, G. LA TORRE, B. CAMPISI, A. TRAFICANTE, M. AIETA, A. CITTADINI (<i>Potenza; Rome, Italy</i>)	1709
Lymph-vascular Space Involvement and Outer One-third Myometrial Invasion Are Strong Predictors of Distant Haematogeneous Failures in Patients with Stage I-II Endometrioid-type Endometrial Cancer. A. GADDUCCI, A. CAVAZZANA, S. COSIO, C. DI CRISTOFANO, R. TANA, A. FANUCCHI, G. TETI, R. CRISTOFANI, A.R. GENAZZANI (<i>Pisa; Massa-Carrara; Latina, Italy</i>)	1715
Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT ₃ Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy. K. TAGUCHI, H. IIHARA, M. ISHIHARA, Y. KOMORI, K. TANIZAWA, K. MATSUURA, Y. ITOH (<i>Gifu, Japan</i>)	1721
Phase I Study of the Sequential Administration of S-1 and Cisplatin for Metastatic Gastric Cancer. E. BABA, H. FUJISHIMA, H. KUSABA, T. ESAKI, H. ARIYAMA, K. KATO, R. TANAKA, K. MITSUGI, Y. SHIBATA, M. HARADA, S. NAKANO (<i>Fukuoka; Kagoshima, Japan</i>)	1727
Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer. T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, M. ADACHI (<i>Tokyo, Japan</i>)	1733
Genetic Alterations in the PI3K Pathway in Prostate Cancer. X. SUN, J. HUANG, T. HOMMA, D. KITA, H. KLOCKER, G. SCHAFFER, P. BOYLE, H. OHGAKI (<i>Lyon, France; Innsbruck, Austria</i>)	1739
Different Biological Materials are Found in Neoplastic Glands with Pores at the Invading Edge of Sporadic Colonic Carcinomas. C.A. RUBIO, C. LENANDER (<i>Stockholm, Sweden</i>)	1745
Efficacy and Feasibility of IDEA Therapy for Refractory or Relapsed Non-Hodgkin's Lymphoma. H. NISHIMORI, N. FUJII, Y. MAEDA, K.-I. MATSUOKA, K. TAKENAKA, K. SHINAGAWA, K. IKEDA, K. MATSUO, M. HARADA, M. TANIMOTO (<i>Okayama; Fukuoka; Nagoya, Japan</i>)	1749
Carboplatin and Vinorelbine Combined with Subcutaneous Interleukin-2 in Metastatic Melanoma with Poor Prognosis. M.-S. VUORISTO, P. VIHINEN, T. SKYTTÄ, K. TYYNELÄ, P. KELLOKUMPU-LEHTINEN (<i>Tampere; Turku; Kuopio, Finland</i>)	1755

Primary Abdominal Wall Clear Cell Carcinoma: Case Report and Review of Literature. C. WILLIAMS, P. PETIGNAT, A. BELISLE, P. DROUIN (<i>Montreal, QC, Canada; Geneva, Switzerland</i>)	1591
Tumor Immune Systems in Esophageal Cancer with Special Reference to Heat-shock Protein 70 and Humoral Immunity. M. NAKAJIMA, H. KATO, T. MIYAZAKI, M. FUKUCHI, N. MASUDA, Y. FUKAI, M. SOHDA, F. AHMAD, H. KUWANO (<i>Gunma, Japan</i>)	1595
High Incidence of Synchronous or Metachronous Breast Cancer in Patients with Malignant and Benign Thyroid Tumor or Tumor-like Disorders. Y. NIO, C. IGUCHI, M. ITAKURA, T. TOGA, K. HASHIMOTO, M. KOIKE, H. OMORI, Y. SATO, S.-I. ENDO (<i>Kyoto; Shimane; Hyogo, Japan</i>)	1607
Mifepristone May Halt Progression of Extensively Metastatic Human Adenocarcinoma of the Colon – Case Report. J.H. CHECK, E. DIX, L. SANSOUCIE, D. CHECK (<i>Camden, NJ, USA</i>)	1611
Microsatellite Instability Does Not Predict the Efficacy of Chemotherapy in Metastatic Colorectal Cancer. A Systematic Review and Meta-Analysis. G. DES GUETZ, B. UZZAN, P. NICOLAS, O. SCHISCHMANOFF, G.-Y. PERRET, J.-F. MORERE (<i>Bobigny, France</i>)	1615
Clinical and Pathological Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Hormonal Receptors, Her2 Status, Grading and Ki-67 Proliferation Index. L. MIGLIETTA, P. VANELLA, L. CANOBBIO, M.A. PARODI, P. GUGLIELMINI, F. BOCCARDO (<i>Genoa, Italy</i>)	1621
Management of Cardiac Adverse Events Occurring with Sunitinib Treatment. M. SCHMIDINGER, A. BOJIC, U.M. VOGL, W. LAMM, C.C. ZIELINSKI (<i>Vienna, Austria</i>)	1627
Genetic Polymorphisms in <i>CYP1A1</i> , <i>CYP1B1</i> , <i>COMT</i> , <i>GSTP1</i> and <i>NAT2</i> Genes and Association with Bladder Cancer Risk in a French Cohort. L. FONTANA, L. DELORT, L. JOUMARD, N. RABIAU, R. BOSVIEL, S. SATHI, L. GUY, J.-P. BOITEUX, Y.-J. BIGNON, A. CHAMOUX, D.J. BERNARD-GALLON (<i>Clermont-Ferrand, France</i>)	1631
Comparison of Robotic-assisted <i>versus</i> Retropubic Radical Prostatectomy Performed by a Single Surgeon. Y.-C. OU, C.-R. YANG, J. WANG, C.-L. CHENG, V.R. PATEL (<i>Taichung, Taiwan, ROC; Orlando, FL, USA</i>)	1637
Comparison of Clofarabine Activity in Childhood and Adult Acute Leukemia: Individual Tumor Response Study. J. STYCZYNSKI, L. GIL, K. DERWICH, J. WACHOWIAK, W. BALWIERZ, W. BADOWSKA, M. KRAWCZUK-RYBAK, M. MATYSIAK, M. WIECZOREK, A. BALCERSKA, D. SONTA-JAKIMCZYK, J. STEFANIAK, J. KOWALCZYK, T. URASINSKI, G. SOBOL, M. KOMARNICKI, M. WYSOCKI (<i>Bydgoszcz; Poznan; Cracow; Olsztyn; Bialystok; Warsaw; Chorzow; Gdansk, Zabrze; Lublin; Szczecin; Katowice, Poland</i>)	1643
The Clinical Significance of Serum Markers of Bone Turnover in NSCLC Patients: Surveillance, Management and Prognostic Implications. E. TERPOS, M. KIAGIA, E.M. KARAPANAGIOTOU, A. CHARPIDOU, K.D. DILANA, E. NASOTHIMIOU, K.J. HARRINGTON, A. POLYZOS, K.N. SYRIGOS (<i>Athens, Greece; London, UK</i>)	1651
CYP17 Gene Polymorphism and its Association in North Indian Prostate Cancer Patients. R.C. SOBTI, L. GUPTA, H. THAKUR, A. SETH, S.K. SINGH, P. KAUR (<i>Chandigarh; New Delhi, India</i>)	1659
Gastric Perforation Presenting as Empyema in a Patient with Pancreatic Cancer on Bevacizumab Treatment. Y.-Y. SHAO, Z.-Z. LIN, P.-C. LIANG, Y.-W. TIEN, A.-L. CHENG (<i>Taipei, Taiwan, ROC</i>)	1665
Reconstruction of Periacetabular Bone Tumor by Vascularized Fibula Graft and Irradiated Autograft. K. MURAMATSU, K. IHARA, Y. TANI, R. IWANAGA, T. TAGUCHI (<i>Yamaguchi, Japan</i>)	1669

Pathological Classification of DCIS and Planning of Therapeutic Management. O. BUONOMO, P. ORSARIA, G. CONTINO, D. VARVARAS, A. GIOIA, E. BONANNO, C. PISTOLESE, E. COSSU, T. PERRETTA, O. SCHILLACI, G. DEL MONTE, M. ROSELLI, T.C. MINEO, G. PETRELLA (<i>Rome, Italy</i>)	1499
Carbon-11-Methionine PET Imaging of Choroidal Melanoma and the Time Course after Carbon Ion Beam Radiotherapy. K. TAMURA, K. YOSHIKAWA, H. ISHIKAWA, M. HASEBE, H. TSUJI, T. YANAGI, K. SUZUKI, A. KUBO, H. TSUJII (<i>Chiba; Tokyo, Japan</i>)	1507
Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan. T. ISHIKAWA, S. SHIMIZU, K. KATAYAMA, T. CHISHIMA, Y. HAMAGUCHI, T. DOI, M. TANABE, A. KASAHARA, N. YAMAGUCHI, K. NARUI, I. OHTA, C. MATSUMOTO, D. SHIMIZU, A. KITO, T. SUDA, M. INABA, T. ASAGA, N. MOMIYAMA, Y. ICHIKAWA, M. YOSHIMOTO, S. MORITA, H. SHIMADA (<i>Tokyo; Kanagawa; Yokohama, Japan</i>)	1515
A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer. Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, S. ADACHI (<i>Nara; Kyoto; Hyogo; Mie; Shiga, Japan; Indianapolis, IN, USA</i>)	1521
Increased Prevalence of Regulatory T-Cells in the Peripheral Blood of Patients with Gastrointestinal Cancer. K. TOKUNO, S. HAZAMA, S. YOSHINO, S. YOSHIDA, M. OKA (<i>Ube, Yamaguchi, Japan</i>)	1527
A Pilot Study of Quality of Life of Patients with Hormone-refractory Prostate Cancer after Gene Therapy. S. TERAOKA, T. SHIRAKAWA, B. ACHARYA, M. MIYATA, N. HINATA, K. TANAKA, A. TAKENAKA, I. HARA, M. NAOE, K. FUJI, T. OKEGAWA, E. HIGASHIHARA, S. KAMIDONO, M. FUJISAWA, A. GOTOH (<i>Nishinomiya; Kobe; Wakayama; Tokyo, Japan</i>)	1533
Assessing the Size of Polyp Phantoms in Tandem Colonoscopies. C.A. RUBIO, C.M. HÖÖG, O. BROSTRÖM, J. GUSTAVSSON, M. KARLSSON, P. MORITZ, R. STIG, O. WIKMAN, L. MATTSSON, D. PALLI (<i>Stockholm, Sweden; Florence, Italy</i>)	1539
Gemcitabine-Capecitabine plus Intra-arterial Epirubicin-Cisplatin in Pretreated Pancreatic Cancer Patients: A Phase I Study. A. MAMBRINI, P. PACETTI, A. DEL FREO, R. DELLA SETA, D. PEZZUOLO, T. TORRI, M. ORLANDI, R. TARTARINI, M. CANTORE (<i>Carrara, Italy</i>)	1547
* Review: Cancer-induced Hypercalcemia. F. LUMACHI, A. BRUNELLO, A. ROMA, U. BASSO (<i>Padova, Italy</i>)	1551
Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer. R.J. BROOM, P.A. TANG, C. SIMMONS, L. BORDELEAU, A.M. MULLIGAN, F.P. O'MALLEY, N. MILLER, I.L. ANDRULIS, D.M. BRENNER, M.J. CLEMONS (<i>Toronto, ON, Canada</i>)	1557
Poster Abstracts of the 1st Capital Congress of the Gynecologic Oncology of the North-Eastern German Society of Gynecological Oncology (<i>Berlin, Germany</i>)	1563
Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer. F. C.-K. CHEN, G. OSKAY-ÖZCELİK, K.J. BÜHLING, U. KÖPSTEIN, M. MENTZE, W. LICHTENEGGER, J. SEHOULI (<i>Berlin, Germany</i>)	1575
DNA Image Cytometry in the Differential Diagnosis of Benign and Malignant Lesions of the Bile Duct, the Pancreatic Duct and the Papilla of Vater. S. BIESTERFELD, L. DEACU (<i>Mainz, Germany</i>)	1579
Usefulness of Current Risk Groups in the Treatment of Surgically Staged Endometrial Carcinomas; A Population-based Study from Western Sweden. G. PAULSSON, A. GENELL, A.-M. JAKOBSEN, G. HORVATH (<i>Skövde; Göteborg, Sweden</i>)	1585